German COVID-19 vaccine CureVac has efficacy rate of 48 percent in final trials

Germany's CureVac said Wednesday that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 percent, far lower than those developed by mRNA rivals BioNTech/Pfizer and Moderna.

The outcome had been expected after poor interim data were released earlier this month.

The company in part blamed "the unprecedented context of 15 strains circulating" among the trial volunteers, as well as varying responses across age groups.

The Covid vaccines developed by Germany's BioNTech in partnership with US giant Pfizer and by US firm Moderna -- based on the same novel messenger RNA technology -- were approved earlier on in the pandemic after showing around 95 percent efficacy.

Their trials only had to contend with the original strain of the virus. But recent studies indicate that both vaccines also offer strong protection against the newer, more contagious variants.

CureVac said its jab, known as CVnCoV, did slightly better among people aged 18 to 60 than among older ages, with efficacy climbing to 53 percent.

Among that same 18-60 age group, the vaccine offered 100-percent protection against hospitalisation and death.

In a statement, chief executive officer Franz-Werner Haas said "CVnCoV demonstrates a strong public health value" for people aged 18 to 60 "which we believe will be an important contribution to help manage the Covid-19 pandemic and the dynamic variant spread".

No safety concerns

CureVac's late-stage Phase 2b/3 trial involved some 40,000 people in 10 countries in Europe and Latin America. Of those, 228 contracted the coronavirus.

CureVac said in May that independent analysis "found no safety concerns" with its two-dose vaccine.

The Tuebingen-based company has shared its data with the European Medicines Agency (EMA), which will now decide if the vaccine is good enough to be greenlit.

CureVac said it would give further details at a press conference on Thursday.

Its share price fell by nearly 10 percent in after-hours trading.

The European Union has secured up to 405 million doses of the CureVac vaccine should it receive regulatory approval.

Despite being a laggard in the vaccine race, CureVac believes it has advantages over mRNA competitors.

CureVac's product can be stored at standard refrigerator temperature, unlike the first-generation Pfizer and Moderna vaccines which require super-cold freezers.

CureVac's vaccine also requires a lower dosage of just 12 microgrammes, compared to 30 microgrammes for BioNTech and 100 for Moderna, allowing for faster and cheaper mass production.

These factors could possibly give CureVac an edge in poorer or warmer countries.

2nd-generation vaccine in development

Scientists have said the weaker-than-hoped results may be down to the lower dosage, or even CureVac's recipe, which unlike its rivals uses an unmodified form of messenger RNA.

The company is already working on a second-generation Covid vaccine for which it has teamed up with pharma giant GSK.

Early results on rats have been promising, it said. Clinical testing on humans is set to begin in the third quarter of 2021.

CureVac was founded in 2000 by mRNA pioneer Ingmar Hoerr and is backed by Dietmar Hopp, the German billionaire behind software behemoth SAP.

The German government last year took a 23-percent stake in CureVac for 300 million euros.

The move came shortly after media reports said then President Donald Trump had sought exclusive US access to any CureVac vaccine, a claim both sides strenuously denied.



from Firstpost Tech Latest News https://ift.tt/3hsc7Ut

Comments

Post a Comment

Popular posts from this blog

COVID-19 origins: Should we pay more attention to the lab leak theory and formally investigate it?

Image
A year and a half into the pandemic, we still do not know exactly where the SARS-CoV-2 virus, which causes Covid-19, came from. The prevailing view so far has been that the virus “spilled over” from bats into humans. But there are increasing calls to investigate the possibility that it emerged from a lab in Wuhan, China, where Covid first appeared at the end of 2019. So what do we know for sure, and what do we need still to find out? We know the sequence of the SARS-CoV-2 virus is close to that of bat coronaviruses . Several decades ago its “ancestor” was circulating in bat populations in southern Asia. But there are still many unanswered questions: we don’t know how the virus arrived in Wuhan, how its sequence evolved to allow human infection, and under what conditions it infected the first people who crossed its path. And for each of these stages, we don’t know whether there was a human contribution (direct or indirect). Zoonotic transmission pathways, in other words the pas
Read more

Menstrual cups are cheaper, more sustainable than pads and tampons for women

Image
Every year in America, women spend at least US$2.8 billion on sanitary pads and tampons that can take hundreds of years to decompose . Is there a more economical and environmentally friendly way? To find out, we asked Susan Powers , a professor of sustainable environmental systems at Clarkson University about her work comparing the environmental impact of tampons, sanitary pads and menstrual cups. What is a menstrual cup? A menstrual cup is a type of reusable feminine hygiene product. It’s a small, flexible bell-shaped cup made of rubber or silicone that a woman inserts into her vagina to catch and collect menstrual fluid. It can be used for up to 12 hours, after which it is removed to dispose of the fluid and cleaned. The cup is rinsed with hot water and soap between each insertion and sterilized in boiling water at least once per period. A cup can last up to 10 years . Although menstrual cups have been around for decades, they historically have been less popular than pads or ta
Read more

Human bodies respond to infections differently depending on the time of day

Image
When microorganisms – such as bacteria or viruses – infect us, our immune system jumps into action. It’s highly trained to sense and eliminate infections and clear up any damage caused by them. It’s typically assumed our immune systems work the exact same way regardless of whether an infection occurs during the day or at night. But research spanning over half a century now shows our bodies actually respond differently at day and night. The reason for this is our body clock, and the fact that each cell in the body, including our immune cells, can tell what time of day it is. Our body clock has evolved over millions of years to help us survive. Every cell in the body has a collection of proteins that indicate the time depending on their levels. Knowing whether it’s day or night means our body can adjust its functions and behaviours (such as when we want to eat) to the correct time. Our body clock does this by generating 24 hour rhythms (also termed circadian rhythms ) in how cells f
Read more